Sofinnova Ventures was to announce on Monday this week that it closed an oversubscribed $440 million fund, its first dedicated entirely to life sciences.

Sofinnova's eighth fund initially had a $325 million target, with an original hard cap of $400 million, the firm's James Healy told BioCentury.